Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 1, 2023

Wild Rivers Waterpark Drops Dates For Camp Wild Rivers Junior Lifeguards, a One-of-a-Kind Weekly Summer Camp for Orange County, • BEST-EVER FIRST QUARTER AND MARCH SALES FOR KIA AMERICA • HONDA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Honda • Statement by the Ministers of Crown-Indigenous Relations, Indigenous Services, and Northern Affairs on the Catholic Church's re • 160 Driving Academy Celebrates Women's History Month • REDWIRE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and D • Why We Need to Ban ChatGPT in Elementary Schools • Bass Named Women In Trucking Association's 2023 Driver of the Year • New Birth Missionary Baptist Church Announces Outreach Activities, Plans for Easter Weekend • REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries • REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the • INVIVYD DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inv • BLOCK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Block • RYVYL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against RYVYL • UNITE HERE Local 11 Rallies with LA Councilmember Curren Price to Endorse Boycott of Tommie and Thompson Hotels • TUP NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Tupperware Brands Corporation Investors to Secure Counsel Before Importa • Statement by Minister Hussen for Sikh Heritage Month • Realty Income Publishes Third Annual Sustainability Report • TGT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Target Corp. Investors with Substantial Losses Have Opp • UNice Hair Launches "UNice Empowering Workshop" Event

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARSIPPANY, N.J. , February 02 /Businesswire/ - IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on February 1, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees. These inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The inducement grants consisted of non-statutory stock options to purchase 368,000 shares of the Company’s common stock and 40,550 restricted stock units for shares of the Company’s common stock.

The stock options have an exercise price of $23.70 per share, equal to the closing price of Iveric Bio’s common stock on February 1, 2023. The stock option grants have a ten-year term and vest over four years, with 25% of the shares underlying the options vesting on February 1, 2024 and an additional 2.0833% of the shares underlying the options vesting at the end of each successive month thereafter. A tranche of 2,650 restricted stock units vests with respect to 100% of the shares underlying the units on April 1, 2023. A tranche of 15,600 restricted stock units vests with respect to 50% of the shares underlying the units on April 1, 2023 and the remaining 50% of the shares underlying the units on July 1, 2023. A tranche of 8,800 restricted stock units vests with respect to 50% of the shares underlying the units on April 1, 2023 and the remaining 50% of the shares on October 1, 2023. A tranche of 3,000 restricted stock units vests with respect to 50% of the shares underlying the units on April 1, 2023 and the remaining 50% of the shares on January 1, 2024. A tranche of 6,000 restricted stock units vests with respect to 100% of the shares underlying the units on January 1, 2024. A tranche of 2,000 restricted stock units vests with respect to 100% of the shares underlying the units on October 1, 2023. A tranche of 2,500 restricted stock units vests with respect to 25% of the shares underlying the units on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

ISEE-G